CombiGene
2.56
SEK
-5.88 %
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-5.88%
0%
+1.59%
-17.42%
-4.83%
-6.57%
-77.85%
-87.99%
-97.33%
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Read moreMarket cap
50.69M SEK
Turnover
54.28K SEK
Revenue
5.54M
EBIT %
-696.75 %
P/E
-
Dividend yield-%
-
Financial calendar
14/2
2025
Annual report '24
ShowingAll content types
CombiGene AB (publ): Valberedning
Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools